Office of Technology Management
Methods and
Compositions for the Treatment and Diagnosis of Shipping Fever
Summary:
Novel
compositions are disclosed for use in the treatment or diagnosis of bovine
pasteurellosis, commonly referred to as Shipping Fever. Cell-free
Pasteurella haemolytica supernatants are employed to provide individual
antigen compositions, identified through reaction with sera from naturally-infected
or convalescent cattle. In particular, at least seven individual
P. haemolytica antigen groups were recognized in cell-free culture supernatants.
Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical
vaccine composition is shown to elicit a specific immune response, in both
cows and rabbits, directed against the individual immunoreactive P. haemolytica
polypeptides identified. Also disclosed are novel recombinant cells,
plasmids and bacteriophage which include transcriptionally active P. haemolytica
antigen genes. Recombinant clones are similarly selected to be reactive
with naturally-infected antisera. Examples, and further disclosure, are
also provided which demonstrate the utility of a presently disclosed antibody
and antigen compositions in immuno-detection of both antigens and antibodies
in various biological samples.
Technology Status:
These
patents are exclusively licensed from UT-Houston Health Science Center.
Dr.
Michael Engler